Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for urgent unmet medical needs. The objective of Panbela’s pipeline is the utilization of pharmacotherapies to reduce/normalize increased disease-associated polyamines using complementary pharmacotherapies. The company’s lead assets are ivospemin (SBP-101), CPP-1X, utilized alone or in combination with Sulindac (Flynpovi™) which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity. These agents target the polyamine pathway at complementary junctions which have been shown to be altered is disease. In particular, our lead assets have the potential to suppress and prevent tumor growth, enhance anti-tumor activity of other anti-cancer agents, and modulate the immune system.
The Company’s development program spans from pre-clinical to registration programs. Late stage programs include ivospemin (SBP-101) for first line metastatic pancreatic cancer and Flynpovi™ for familial adenomatous polyposis (FAP).